The novel coronavirus disease 2019 (COVID‐19) emerged in late December 2019 in china
and has rapidly spread to many countries around the world. The effective pharmacotherapy …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …

Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …

As of May 2022, there have been over 524 million confirmed cases of COVID-19 (10). The
pandemic has thus far claimed approximately 6.2 million lives (10). Vaccination is having a …

Updates This is the fourteenth version (thirteenth update) of the living guideline, replacing
earlier versions (available as data supplements). New recommendations will be published …

The evidence base for therapeutics for covid-19 is evolving with numerous randomised
controlled trials (RCTs) recently completed and under way. This update adds new …

There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer
developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro …

The emergence of SARS-CoV-2 variants of concern (VoCs) has exacerbated the COVID-19
pandemic. Currently available monoclonal antibodies and vaccines appear to have reduced …

As the SARS-CoV-2 pandemic remains uncontrolled owing to the continuous emergence of
variants of concern, there is an immediate need to implement the most effective antiviral …

Broad‐spectrum antiviral agents targeting viral RNA‐dependent RNA polymerase (RdRp)
are expected to be a key therapeutic strategy in the ongoing coronavirus disease 2019 …